Opportunities for Cooperative Research and Development Agreements (CRADAs) To Undertake Research and Development of Compounds From Specific Categories for the Treatment of Drug Dependence

Riepilogo

The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health, is seeking proposals from potential collaborators for one or more Cooperative Research and Development Agreements (CRADAs) to test, by scientific means meeting U.S. Food and Drug Administration (FDA) standards, the hypothesis that compounds representative of the following classes (numbered 1-8 below) may be useful in the treatment of drug dependence: 1. CRF-1 antagonists. 2. Cannabinoid-1 antagonists. 3. MGluR5 antagonists. 4. AMPA antagonists. 5. Selective, high affinity dopamine D3 agonists and antagonists. 6. Selective, high affinity dopamine D1 full or partial agonists. 7. Kappa opioid antagonists. 8. Compounds from classes not named in 1-7 above, but for which compelling rationales are provided by potential collaborators.